Literature DB >> 8634990

The molecular basis of ovarian cancer.

H H Gallion1, M Pieretti, P D DePriest, J R van Nagell.   

Abstract

BACKGROUND: Molecular genetic studies of ovarian cancer have been limited by the inaccessible location of the ovary, the advanced stage of tumors available for analysis, and the lack of a well-defined precursor lesion. However, genetic alterations important in ovarian tumorigenesis have been identified recently.
METHODS: Molecular genetic evaluation of ovarian cancer primarily has utilized mutation analysis, immunohistochemical techniques, and loss of heterozygosity (LOH) studies.
RESULTS: Overexpression of the HER-2/neu oncogene is present in approximately one third of ovarian cancers and is associated with poor prognosis. Mutations of the K-ras oncogene have been identified in a similar proportion of mucinous ovarian tumors, including borderline tumors. The study authors as well as others have frequently detected LOH on chromosome 17, including the p53 and BRCA1 loci, and at 17p3.3 and 1717q22-23. Genetic linkage analysis indicates that the majority of inherited ovarian cancers are caused by mutations in the BRCA1 gene. Mutations in mismatch repair genes have been identified in ovarian cancers that occur as part of the hereditary nonpolyposis colon cancer syndrome.
CONCLUSIONS: Sporadic ovarian tumors are the end result of a complex pathway involving multiple oncogenes and tumor suppressor genes, including HER-2/neu, K-ras, p53, BRCA1, and additional tumor suppressor genes on chromosome 17. The majority of inherited ovarian cancers are due to mutations in the BRCA1 gene, which appears to be a tumor suppressor gene. It is hoped that an increased understanding of the molecular basis of ovarian cancer will lead to advances in prevention, diagnosis, and treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8634990     DOI: 10.1002/1097-0142(19951115)76:10+<1992::aid-cncr2820761315>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  RNA polymerase III transcription factor TFIIIC2 is overexpressed in ovarian tumors.

Authors:  A G Winter; G Sourvinos; S J Allison; K Tosh; P H Scott; D A Spandidos; R J White
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

2.  Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.

Authors:  Gregory T Langland; Steven M Yannone; Rachel A Langland; Aki Nakao; Yinghui Guan; Sydney B T Long; Lien Vonguyen; David J Chen; Joe W Gray; Fanqing Chen
Journal:  Oncol Rep       Date:  2010-04       Impact factor: 3.906

3.  GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt.

Authors:  Deborah A Altomare; Lili Zhang; Jing Deng; Antonio Di Cristofano; Andres J Klein-Szanto; Rakesh Kumar; Joseph R Testa
Journal:  Clin Cancer Res       Date:  2010-01-15       Impact factor: 12.531

4.  Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.

Authors:  Sandra Orsulic; Yi Li; Robert A Soslow; Lynn A Vitale-Cross; J Silvio Gutkind; Harold E Varmus
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

5.  Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients.

Authors:  K P Hickey; K P Boyle; H M Jepps; A C Andrew; E J Buxton; P A Burns
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.